A once-promising drug to fight Alzheimer’s by biotech company TauRx has failed in clinical trials, where it performed no better than a placebo. The treatment is however being tested in another study, with results expected in coming months. With roughly 15 percent of Alzheimer’s treatments having failed in the decade between 2002 and 2012, the market for effective treatments is valued at over $10bn per year.
A once-promising drug to fight Alzheimer’s by biotech company TauRx has failed in clinical trials, where it performed no better than a placebo. The treatment is however being tested in another study, with results expected in coming months. With 99.6% of Alzheimer’s treatments having failed in the decade between 2002 and 2012, the market for effective treatments is valued at over $10bn per year.